Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ANGIODYNAMICS, INC.

(ANGO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

AngioDynamics : to Present at the Canaccord Genuity Virtual Growth Conference

07/29/2021 | 04:03pm EDT

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the 41st Annual Canaccord Genuity Virtual Growth Conference at 9:00 a.m. ET on Wednesday, August 11, 2021.

A live webcast of the presentation will be accessible through the “Investors” section of the Company’s website at www.angiodynamics.com and will be available for replay following the event.

About AngioDynamics, Inc.

AngioDynamics, Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, peripheral vascular disease, and oncology. AngioDynamics’ diverse product lines include market-leading ablation systems, vascular access products, angiographic products and accessories, drainage products, thrombolytic products, and venous products. For more information, visit www.angiodynamics.com.


© Business Wire 2021
All news about ANGIODYNAMICS, INC.
09/15ANGIODYNAMICS : to Report Fiscal 2022 First Quarter Financial Results on Septemb..
BU
08/30ANGIODYNAMICS : New AMA Category III CPT Code Issued for Transcatheter Removal/D..
PU
08/20ANGIODYNAMICS : Oppenheimer Initiates Coverage on AngioDynamics With Perform Rat..
MT
08/17INSIDER TRENDS : Insider at AngioDynamics Acquires Stock Via Conversion of Optio..
MT
08/12ANGIODYNAMICS : Receives FDA Approval for PRESERVE Study
PU
07/29ANGIODYNAMICS : to Present at the Canaccord Genuity Virtual Growth Conference
BU
07/27ANGIODYNAMICS : Management's Discussion and Analysis of Financial Conditions and..
AQ
07/23INSIDER TRENDS : AngioDynamics Insider Gets Shares Award Makes Tax Sale with Por..
MT
07/14ANGIODYNAMICS : Canaccord Genuity Adjusts Price Target on AngioDynamics to $28 F..
MT
07/13ANGIODYNAMICS : rsquo; Fiscal 2021 Fourth Quarter Financial Results
PU
More news
Analyst Recommendations on ANGIODYNAMICS, INC.
More recommendations
Financials (USD)
Sales 2022 308 M - -
Net income 2022 -15,2 M - -
Net Debt 2022 - - -
P/E ratio 2022 -65,5x
Yield 2022 -
Capitalization 973 M 973 M -
Capi. / Sales 2022 3,16x
Capi. / Sales 2023 2,93x
Nbr of Employees 800
Free-Float 95,6%
Chart ANGIODYNAMICS, INC.
Duration : Period :
AngioDynamics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ANGIODYNAMICS, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 25,31 $
Average target price 30,00 $
Spread / Average Target 18,5%
EPS Revisions
Managers and Directors
James Christopher Clemmer President, Chief Executive Officer & Director
Stephen A. Trowbridge Chief Financial Officer & Executive Vice President
Howard W. Donnelly Independent Non-Executive Chairman
David D. Helsel SVP-Global Operations, Research & Development
Kim L. Seabury Senior Vice President-Information Technology
Sector and Competitors